Regulation of thrombosis and hemostasis by antithrombin

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 6, 1997, Pages 557-562

  Sakuragawa, Nobuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Antithrombin; Heparin cofactor II; Hepatocellular carcinoma; Herbal drugs; Vessel wall

Indexed keywords

ANTITHROMBIN; HEPARIN COFACTOR II; LOW MOLECULAR WEIGHT HEPARIN;

ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; CONFERENCE PAPER; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBIN TIME; THROMBOSIS;

EID: 0031409608     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996136     Document Type: Conference Paper

References (55)

1. Seegers WH, JF Johnson, C Fell: An antithrombin reaction related to prothrombin activation. Am J Physiol 176:97-103, 1964.
2. Seegers WH, LE McCoy, HD Groben, N Sakuragawa: Purification and some properties of autoprothrombin II-A: An anticoagulant perhaps also related to fibrinolysis. Thromb Res 1:443-506, 1972.
3. Sakuragawa N, K Takahashi, S Kondo, T Koide: Antithrombin III "Toyama": A hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 31:305-317, 1983.
4. 393-His substitution. Acta Med Biol 43:157-163, 1995.
5. Akiyama K, K Nakamura, I Makino, Y Takeda, K Kubota, S Tazawa, T Hayashi, K Niiya, N Sakuragawa: Antithrombin III-producing hepatocellular carcinoma. Thromb Res 72:193-201, 1993.
6. Shiozaki A, T Arai, R Izumi, K Niiya, N Sakuragawa: Congenital antithrombin III-deficient neonate treated with antithrombin concentrates. Thromb Res 70:211-216, 1993.
7. Lane DA, RT Olds, M Boisclair, V Chowdhury, SL Thein, DN Cooper, M Blajchman, D Perry, J Emmerich, M Aiach: Antithrombin III: A database of mutations: First update. Thromb Haemostas 70:361-369, 1993.
8. Olds RT, DA Lane, V Chowdhury: Complete nucleotide sequence of the antithrombin gene: Evidence for homologous recombination causing thrombophilia. Biochemistry 32:4216-4224, 1993.
9. Thaler E, K Lechner: Antithrombin III deficiency and thromboembolism. Clin Hematol 10:369-390, 1981.
10. Heren T, PW Straub, A Haeberli: Prothrombin fragment 1+2, thrombin-antithrombin III complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Thromb Haemostas 71:49-53, 1994.
11. Saito S, K Takahashi, N Sakuragawa: Interaction of abnormal antithrombin III "Toyama" with cultured porcine aortic endothelial cells. Thromb Res 50:19-25, 1988.
12. Enomoto M, T Tanimizu, N Sakuragawa: Antithrombin III assay without influence of heparin cofactor II. Thromb Res 57:729-736, 1990.
13. Yoshida Y, M Kobayashi, N Sakuragawa: Efficacy of antithrombin concentrates in treatment of asthmatic symptoms complicated in antithrombin abnormality with no heparin binding activity. Clin Appl Thromb Hemostas 3:288-289, 1997.
14. Yamagishi R, M Niwa, S Kondo, T Koide, N Sakuragawa: Purification and biological property of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans. Thromb Res 36:633-642, 1984.
15. Sakuragawa N: Blood coagulation and its modulating system. Jpn J Med 26:99-101, 1987.
16. Sakuragawa N: New molecular markers to detect thrombotic state. Med Practice 11:103-106, 1994 (Japanese).
17. 189 to His decreases the affinity for dermatan sulfate. J Biol Chem 26:5128-5133, 1989.
18. Tran TH, GA Marbet, F Duckert: Association of hereditary heparin cofactor II deficiency and thrombosis. Lancet 8425: 413-414, 1985.
19. Tollefsen DM, DW Majerus, MK Blank: Heparin cofactor II: Purification and properties of heparin-dependent inhibition in human plasma. J Biol Chem 257:2162-2169, 1982.
20. Simioni P, AR Lazzaro, E Coser, G Salmistaro, A Girolami: Hereditary heparin cofactor II deficiency and thrombosis: Report of six patients belonging to two separate kindreds. Blood Coag Fibrinolysis 1:351-356, 1990.
21. Toulon P, L Moulonguet-Doleris, JM Costa, M Aiach: Heparin cofactor II deficiency in renal allograft recipients: No correlation with development of thrombosis. Thromb Haemostas 65: 20-24, 1991.
22. Weisdorf DJ, JR Edson: Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II. Br J Haematol 77:125-126, 1991.
23. Matsuo T, K Kario, S Sakamoto, T Yamada, T Miki, T Hirase, H Kobayashi: Hereditary heparin cofactor II deficiency and coronary artery disease. Thromb Res 65:495-505, 1992.
24. Simoni P, S Zanardi, P Pradoni, A Girolami: Combined inherited protein S and heparin cofactor II deficiency in a patient with upper limb thrombosis: A family study. Thromb Res 67:23-30, 1992.
25. Jobin F, L Vu, M Lessard: Two cases of inherited triple deficiency in a large kindred with thrombotic diathesis and deficiencies: Antithrombin III, heparin cofactor II and protein C and protein S. Thromb Haemostas 66:295-299, 1991.
26. Toulon P, M Lamine, I Ledjiev, T Guez, ME Holleman, D Sereni, D Sicard: Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus. Thromb Haemostas 70:730-735, 1993.
27. 1-antitrypsin, antithrombin, and the mechanism of inflammatory thrombosis. Nature 317:730-732, 1985.
28. Jordan RE, J Kilpatrick, RM Nelson: Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 237:777-779, 1987.
29. Sie P, D Dupouy, F Dol, B Boneu: Inactiviation of heparin cofactor II by polymorphonuclear leukocytes. Thromb Res 47: 657-663, 1987.
30. Hoffman M, CW Pratt, RL Brown, FC Church: Heparin cofactor II-protease reaction products exhihit neutrophil chemoattractant activity. Blood 73:1682-1685, 1989.
31. Corbin LW, FC Church, M Hoffman: Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. Thromb Res 57:77-85, 1990.
32. Kopp CB, P Ducimetiere, PJ Touboul: Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation 89:952-954, 1994.
33. Rakugi H, DK Kim, JE Krieger, DS Wang, VJ Dzau, RE Pratt: Induction of angiotensin-converting enzyme in the neointima after vascular injury. J Clin Invest 93:339-346, 1994.
34. Rasmussen LM, L Heickendorff: Accumulation of fibronectin in aortas from diabetic patients. A quantitative immunohistochemical and biochemical study. Lab Immunol 61:440-446, 1989.
35. Iademarco MF, JJ McQuillan, GD Rosen, DC Dean: Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 267:16323-16329, 1992.
36. Hynes OR: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992.
37. 4 subunit cDNA. J Cell Biochem 51:465-478, 1993.
38. 1-integrins, cytoskeletal proteins, and tyrosine phosphorylated substrates during integrin-mediated leukocyte aggregation. J Immunol 151:3817-3828, 1993.
39. 1-integrin chain. J Biol Chem 269:6124-6132, 1994.
40. Ohno T, D Gordon, H San, VJ Pomili, MJ Imperiale, GJ Nabel, EG Nabel: Gene therapy for vascular smooth muscle cell proliferation after injury. Science 265:781-784, 1994.
41. Akai T, T Kaji, Y Hayakawa, T Hayashi, N Sakuragawa: Antithrombin III modulates the effect of thrombin on the metabolism of glycosaminoglycans in cultured endothelial cells. Thromb Res 62:707-716, 1991.
42. Vu TKH, DT Hung, VT Wheaton, SR Coughlin: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068, 1991.
43. Coughin SR: Thrombin receptor structure and function. Thromb Haemostas 66:184-87, 1991.
44. Vassallo RR, T Kieber-Emmons, K Cichowski, LF Brass: Structure-function relationship in the activation of platelet thrombin receptor by receptor-derived peptide. J Biol Chem 267:6081-6085, 1992.
45. Kaji T, N Sakuragawa: Heparin stimulates the release of glycosaminoglycans from cultured human endothelial cells. Thromb Res 57:163-168, 1990.
46. Kaji T, F Itoh, Y Hayakawa, Y Oguma, N Sakuragawa: Interaction of thrombin with heparin cofactor II and antithrombin III on prostacyclin production by cultured endothelial cells. Thromb Res 56:99-108, 1989.
47. Kaji T, N Ejiri, Y Hayakawa, T Hayashi, N Sakuragawa: Heparin cofactor II inhihits thrombin-stimulated release of tissue plasminogen activator from cultured human endothelial cells in the presence of dermatan sulfate. Thromb Res 59:269-277, 1990.
48. Hayakewa Y, S Tazawa, N Sakuragawa, et al: Thrombin regulation of tissue-type plasminogen activation synthesis in cultured human fetal lung fibroblasts. Thrombos Res 71:457-465, 1993.
49. Matsuoka M, N Sakuragawa, K Takahashi: Thrombolytic therapy using urokinase. Medical Postgraduates 12:180-190, 1964.
50. Sakuragawa N, K Shimizu: Studies on effects of PEG-modified urokinase. Thrombos Res 41:629-635, 1986.
51. Sakuragawa N, M Maki, M Hasegawa, et al: Clinical evaluation of low molecular weight heparin. Thrombos Res 72:475-500, 1993.
52. Sakuragawa N: Studies on Wakan-Yakus (traditional drugs): Inhibitory effects of Gaiyoh (Artemisia folium) and Sanshishi (Gardenia fructus) on blood coagulation. Acta Med Biol 32:107-113, 1984.
53. Hayashi T, T Kaji, N Sakuragawa, et al: Stimulants from Gardeniae fructus for cultured endothelial cell proliferation. Chem Pharm Bull 38:942-945, 1992.
54. Kaji T, N Sakuragawa: A stimulatory effect of Artemisia leaf extracts on the proliferation of cultured endothelial cells. Chem Pharm Bull 38:538-540, 1990.
55. Bertina RM, BPC Koeleman, T Koster, et al: Mutation in bood coagulation factor V associated with resistance to activated protein C. Nature 369(5):64-67, 1994.